Blinatumoab公司
CD19
淋巴瘤
医学
B细胞
单克隆抗体
抗体
嵌合抗原受体
弥漫性大B细胞淋巴瘤
临床试验
药品
免疫学
T细胞
癌症研究
肿瘤科
内科学
药理学
免疫系统
作者
David Sermer,Pavania Elavalakanar,Jeremy S. Abramson,M. Lia Palomba,Gilles Salles,Jon Arnason
出处
期刊:Blood Reviews
[Elsevier]
日期:2023-01-01
卷期号:57: 101002-101002
被引量:11
标识
DOI:10.1016/j.blre.2022.101002
摘要
CD19 is nearly ubiquitously expressed on B-lymphocytes and in B-cell malignancies. Although CD19-directed CAR T cells have greatly improved outcomes in B-cell malignancies, there are significant limitations with this therapy. CD19 can also be effectively targeted by other drug classes, such as monoclonal antibodies, antibody-drug conjugates, and bispecific T cell engagers or antibodies. However, the optimal patient selection and sequencing of these novel therapies has not yet been established. In this review, we discuss the utilization of CD19 as a target for the treatment of DLBCL, focusing on tafasitamab, loncastuximab tesirine, and blinatumomab. We provide a comprehensive review of the pivotal clinical trials, discussing the strength and limitations of the data for each agent. We explore the emerging evidence that CD19 expression is retained following exposure to these agents and that patients can be successfully re-challenged with anti-CD19 therapies of a different drug class upon disease relapse post-CAR T cells. Finally, we discuss how these drugs potentially fit into the most current treatment paradigm for DLBCL.
科研通智能强力驱动
Strongly Powered by AbleSci AI